Fiscal Year 2007 - Department of Medicine - University of ...

78
Sponsor and Title: Robert Wood Johnson Foundation,
“Expecting Success: Excellence in Cardiac
Care through Improving the Continuum of Care
for Minority Patients”
Principal Investigator: Michael Winniford
Project Period: 09/15/2005-02/14/2008
Annual Funding: $199,298
Sponsor and Title: Robert Wood Johnson Foundation,
“Improving Heart Care using the Patient
Activation Measure and Customized Patient Support”
Principal Investigator: Michael Winniford
Project Period: 12/01/2006-11/30/2008
Annual Funding: $8,295
Sponsor and Title: Novaris Pharmaceuticals, “A
Randomized, Double-Blind, Placebo-Controlled,
Multi-center Study of the Efficacy and Safety of
Long Term Administration of Nateglinide and
Valsartan in the Prevention of Diabetes and Cardiovascular
Outcomes in Subjects with Impaired
Glucose Tolerance” (NAVIGATOR)
Principal Investigator: Marion R. Wofford
Project Period: 12/01/2002-12/31/2009
Annual Funding: $107,972
Sponsor and Title: NHLBI, “Clinical Trial of
Dietary Protein on Blood Pressure”
Principal Investigator: Marion R. Wofford
Project Period: 07/01/2004-06/30/2007
Annual Funding: $1,109,287
Sponsor and Title: Mylan/Bertek Pharmaceuticals,
“ A Double-Blind, Randomized, Placebo-and
Active-Controlled, Forced Titration Study Evaluating
the Effects of Nevivolol on Blood Pressure
and Heart Rate in African American Patients with
Hypertension”
Principal Investigator: Marion R. Wofford
Project Period: 04/01/2005-12/01/2006
Annual Funding: $43,601
Sponsor and Title: Novartis Pharmaceuticals, “A
54-Week, Open Label, Multi-center Study to Assess
the Long-Term Safety and Combination of
Aliskiren 300 mg/Valsartan 320 mg in Patients
with Essential Hypertension (Aliskiren 2301).”
Principal Investigator: Marion R. Wofford
Project Period: 07/01/2006-08/31/2008
Annual Funding: $102,755
Sponsor and Title: Novartis Pharmaceuticals, “A
Multi-center, Randomized, Double-Blind, Active
Controlled Study to Compare the Effect of 24
Weeks Treatment with Vildagliptin 100 mg qd or
Metformin 1500 mg daily in Elderly Drug Naïve
Patients with Type 2 Diabetes (CLAF).”
Principal Investigator: Marion R. Wofford
Project Period: 08/01/2006-08/31/2008
Annual Funding: $51,940
Sponsor and Title: Novartis Pharmaceuticals, “A
10-Week, Multi-center, Randomized, Double-
Blind, Parallel-Group, Forced-Titration Study
Using 24-Hr ABPM to Evaluate the Efficacy of a
Valsartan/Hydrochlorothiazide (HCTZ) Treatment
Regimen Versus Conventional Treatment
Regimen with Amlodipine and Hydrochlorothiazide
(HCTZ) in Patients with Stage 2 Hypertension
(EVALUATE).”
Principal Investigator: Marion R. Wofford
Project Period: 11/08/2006-07/31/2008
Annual Funding: $29,400
Sponsor and Title: HHS, “Retaining African
American Research Participation using a Community
Driven Model”
Principal Investigator: Sharon B. Wyatt
Project Period: 10/01/2005-09/30/2006
Annual Funding: $44,999
Sponsor and Title: NIH, “Excellence in Partnerships
for Community Outreach, Research on
Health Disparities and Training”
Principal Investigator: Sharon B. Wyatt
Project Period: 9/1/2006-8/31/2007
Annual Funding: $25,000